newsfilter
← Latest News
GlobeNewswire·

Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

• Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022• Reported Positive Effects in TSC Altitude Trial• Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Securities• Expected